tbuckley/cabot-search huggingface dataset:
Tattoo
Authors: Michael L. Willoughby
Journal: Annals of Internal Medicine (2003)

On Being a Doctor4 November 2003TattooMichael L. Willoughby, MDMichael L. Willoughby, MDFrom Augusta, GA 30904.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-139-9-200311040-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail He didn't feel very likable when he was on call. He must have made his family just as miserable as he made himself, since they seemed to dread his call days almost as much as he did. At least they no longer took his on-call moodiness personally, and they didn't avoid him as much. At home, he jumped when the phone rang and became irritable at least a week before a long weekend on call. This call day was unexpected, and he was grateful that he hadn't had time to dread it. It had been a long day, but he ... Author, Article, and Disclosure InformationAffiliations: From Augusta, GA 30904.Corresponding Author: Michael L. Willoughby, MD, 2258 Wrightsboro Road, Suite 200, Augusta, GA 30904; e-mail, [email protected]org. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 4 November 2003Volume 139, Issue 9Page: 789KeywordsAllergy and immunologyAntibioticsAnxietyChartsEmergency departmentHearingMemorySleepSmell ePublished: 4 November 2003 Issue Published: 4 November 2003 Copyright & PermissionsCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
SMALLPOX AT BAY
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Survival in Academy Award–Winning Actors and Actresses
Authors: Donald A. Redelmeier
Journal: Annals of Internal Medicine (2003)

Letters7 January 2003Survival in Academy Award–Winning Actors and ActressesDonald A. Redelmeier, MD and Sheldon Singh, MDDonald A. Redelmeier, MDSunnybrook and Women's Hospital Toronto, 4N 3M5, Canada (Redelmeier, Singh)Search for more papers by this author and Sheldon Singh, MDSunnybrook and Women's Hospital Toronto, 4N 3M5, Canada (Redelmeier, Singh)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-138-1-200301070-00025 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We received a substantial amount of attention related to our research, including coverage by Science, Scientific American, Time, People, and late-night talk shows. We also received more than 50 detailed e-mail messages from those in the academic community with comments and questions. Staud and Miskie and colleagues raise two separate points but understate the diversity of the outside perspectives we encountered.Staud claims that we did not consider undetermined factors that may contribute to both lifespan and personal achievement. We appreciate that cohort studies are prone to subtle biases, yet our analyses tested for many forms of confounding ... Author, Article, and Disclosure InformationAuthors: Donald A. Redelmeier, MD; Sheldon Singh, MDAffiliations: Sunnybrook and Women's Hospital Toronto, 4N 3M5, Canada (Redelmeier, Singh) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSurvival in Academy Award–Winning Actors and Actresses Donald A. Redelmeier and Sheldon M. Singh Survival in Academy Award–Winning Actors and Actresses Roland Staud Survival in Academy Award–Winning Actors and Actresses Brooke Miskie , Susan Near , and Robert Hegele Metrics Cited byLong-term mortality of academy award winning actors and actresses 7 January 2003Volume 138, Issue 1Page: 78KeywordsCohort studiesScientistsSurvival analysis ePublished: 7 January 2003 Issue Published: 7 January 2003 Copyright & PermissionsCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Y chromosome variation of mice and men.
Authors: M W Nachman
Journal: Molecular Biology and Evolution (1998)

DNA sequences from the nonrecombining portion of the Y chromosome were compared with autosomal and X-linked sequences from mice and humans to test the neutral prediction that ratios of polymorphism to divergence are the same for different genes. Intraspecific variation within Mus domesticus was compared with divergence between M. domesticus and Mus caroli for Sry, a region 5' to Sry, and four X-linked genes, Hprt, Plp, Amg, and Glra2. None of these comparisons revealed significantly reduced variation on the Y chromosome. Intraspecific variation within humans was compared with divergence between humans and chimpanzees for three Y-linked loci (Zfy, the YAP region, and the Sry region), seven X-linked loci (Il2rg, Plp, Hprt, Gk, Ids, Pdhal, and Dmd), and the beta-globin locus on chromosome 11. In these comparisons, the observed level of variation on the human Y chromosome was slightly lower than expected, but was significantly lower in only one case (Sry region vs. Dmd). These results suggest that the levels of variability on the Y chromosome in mice and humans are close to expected values given the effective population size and mutation rates for these loci. There is at most only a modest reduction in variability that may be attributed to natural selection (either genetic hitchhiking or background selection).
EARLY HISTORY OF THORACIC SURGERY
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inhalation of Tetramethyl Lead and Tetraethyl Lead: Effects in Rats and Dogs
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MILIGNANT MELANOMA
Authors: D. C. Bodenham
Journal: British Journal of Dermatology (1968)

Journal Article MILIGNANT MELANOMA Get access D. C. Bodenham D. C. Bodenham Frenchay Hospital, Bristol Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 80, Issue 3, 1 March 1968, Pages 190–192, https://doi.org/10.1111/j.1365-2133.1968.tb12291.x Published: 01 March 1968
THE DISEASES OF THE EARLY EGYPTIANS
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2469: The COSMIC Cancer Gene Census - a comprehensive study of all mutated cancer-driving genes
Authors: Zbyslaw Sondka, Helen E. Speedy, Sally Bamford, Charlotte G. Cole, Sari A. Ward, Simon A. Forbes
Journal: Cancer Research (2019)

Abstract The COSMIC Cancer Gene Census (https://cancer.sanger.ac.uk/census) is a catalogue of genes that drive all forms of human cancer. Since 2004, a consistent curation approach to the scientific literature has grown this resource into a comprehensive description of 723 genes, detailing how each gene contributes to disease causation The entire Cancer Gene Census has been fully re-evaluated, and each gene has been classified as Oncogene, Tumour Suppressor and/or Fusion gene - depending on their somatic mutation profile and functional role in carcinogenesis. Genes included in the CGC are characterised by the presence of somatic or germline mutations, which change the activity or expression of the protein product in a way that promotes one or multiple hallmarks of cancer. The minimum level of evidence required for CGC inclusion are at least 2 publications from independent research groups showing increased mutation frequency in at least one type of cancer; and 2 or more published experimental evidence of functional involvement of a gene in promoting the hallmarks of cancer. The functional description of how each mutated gene causes cancer is now underway, with approximately half the Census now described in both functional and mechanistic terms. These characteristics clearly show that many genes can participate in oncogenesis in multiple ways that are highly dependent on the type of genetic alteration and tissue in which the gene is expressed, as well as disease stage. Alongside this evidence-based characterisation of genes we know drive cancer, a “second tier” of genes is now encompassed in the Census, to describe genes implicated in oncology, but with less robust published evidence. These genes, often revealed by combining whole-tumour-genome sequencing studies are increasing rapidly in number and often underpin exciting new targets in oncology. Inclusion of these in the Census completes its ability to describe the contribution of inherited and acquired genetics to human oncology. With substantial research ongoing, the Census is updated with additional content every three months, included with every new release of the COSMIC database (https://cancer.sanger.ac.uk/). Citation Format: Zbyslaw Sondka, Helen E. Speedy, Sally Bamford, Charlotte G. Cole, Sari A. Ward, Simon A. Forbes. The COSMIC Cancer Gene Census - a comprehensive study of all mutated cancer-driving genes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2469.
GUAYAQUIL
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Unwilling executioners?
Authors: Sophie Arie
Journal: BMJ (2011)

We evaluated CD8<sup>+</sup> T cell responses against the dominant CTL epitope, OVA<sub>257–264</sub>, expressed by an acute (<i>Listeria monocytogenes</i> (<i>LM</i>) OVA) vs a chronic pathogen (<i>Mycobacterium bovis</i> bacillus Calmette-Guérin (BCG) OVA) to reveal the influence on CD8<sup>+</sup> T cell memory and consequent protection against a challenge with OVA-expressing tumor cells. Infection with lower doses of both pathogens resulted in stronger bacterial growth but weaker T cell memory indicating that memory correlates with pathogen dose but not with bacterial expansion. The CD8<sup>+</sup> T cell response induced by <i>LM</i>-OVA was helper T cell-independent and was characterized by a rapid effector response followed by a rapid, but massive, attrition. In contrast, BCG-OVA induced a delayed and weak response that was compensated for by a longer effector phase and reduced attrition. This response was partly dependent on CD4<sup>+</sup> T cells. CD8<sup>+</sup> T cell response induced by BCG-OVA, but not <i>LM</i>-OVA, was highly dependent on pathogen persistence to compensate for the weak initial CD8<sup>+</sup> T cell priming. Despite a stronger initial T cell response with <i>LM</i>-OVA, BCG-OVA provided more effective tumor (B16OVA) control at both local and distal sites due to the induction of a persistently activated acquired, and a more potent innate, immunity.
Book Review The First Five Years of Life: A guide to the study of the preschool child . From the Yale Clinic of Child Development. Part I by Arnold Gesell, Ph.D., M.D.; Part II by Henry M. Halverson, Ph.D., Helen Thompson, Ph.D., Frances L. Ilg, M.D., Burton M. Castner, Ph.D., and Louise Bates Ames, Ph.D.; Part III by Arnold Gesell and Catherine S. Amatruda, M.D. 8°, cloth, 393 pp., with 21 plates. New York: Harper &amp; Brothers, 1940. $3.50.
Journal: New England Journal of Medicine (1940)
Author Index Vol. 69, No. 4, 2000
Authors: Tatjana Sivik, Thomas N. Wise, Piero Porcelli, Massimo De Carne, Giovanni A. Fava, Kurt Kroenke, Ralph Swindle, N. Sonino, M. Boscaro, F. Fallo, G.A. Fava, M. Rigatelli, S. Ferrari, U. Uguzzoni, A. Natali, Giovanni A. Fava, Carol D. Ryff, Burton H. Singer, Giovanni A. Fava, Nicoletta Sonino
Journal: Psychotherapy and Psychosomatics (2000)
Intensive up-front treatment versus a sequential approach in advanced gastric cancer patients: Does first line matter?
Authors: Alessandro Bittoni, Mario Scartozzi, Mirco Pistelli, Eva Galizia, Michela Del Prete, Riccardo Giampieri, Luca Faloppi, Maristella Bianconi, Elena Maccaroni, Stefano Cascinu
Journal: Journal of Clinical Oncology (2012)

131 Background: The definition of the standard chemotherapy regimen for advanced gastric cancer is still a matter of debate. A recent meta-analysis suggested that the addition of a third drug to a doublet regimen should be considered the state-of-the-art strategy to improve overall survival. Aim of our analysis was to retrospectively assess whether an intensive, three-drugs, front line approach could be comparable to a sequential (two-drugs front line then second line) in terms of RR (response rate), PFS (progression free survival), and OS (overall survival) in advanced gastric cancer patients. Methods: Patients with metastatic gastric cancer who have received a first-line combination chemotherapy with a two or three-drugs regimen were included in our analysis. We divided our patients into two groups, A and B, based on the first line chemotherapy administered (group A=three drugs; group B= two drugs). Results: A total of 390 patients were eligible for our analysis. 211 patients (54%) received three chemotherapeutic agents (group A) and 179 patients (46%) received a two drugs regimen as first-line combination chemotherapy (group B). The 2 groups of patients resulted comparable for all known prognostic factors of clinical relevance. RR for group A and B was 46,5% and 28%, respectively (p=0,0007), median PFS was 7,12 months in group A and 3,96 months in group B (p&lt;0,0001). No significantly difference resulted for the median OS of patients in the two groups (13 months for group A and 11,8 months for group B; p= 0,962). Conclusions: The addition of a third drug to a doublet chemotherapy regimen appeared more active in terms of response rate and PFS. However median OS resulted comparable. On this basis, a triplet regimen may represent an optimal choice, particularly when response and PFS are relevant treatment endpoints. Nevertheless the use of a sequential approach may also represent a reasonable strategy for patients unwilling or unable to undergo a more intensive treatment without compromising OS.
PRACTICAL SCIENTIFIC WORK.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Defibrillation
Authors: W. A. Tacker
Journal: JAMA (1976)

<h3>To the Editor.—</h3> The excellent review article on cardiac arrest (232:845, 1975) is an important contribution to the subject of defibrillation. We, like Dr Loeb, have observed defibrillation failures caused by technical problems and, therefore, desire to emphasize some recent information on defibrillators and defibrillation that may help to overcome many of these problems. Techniques and equipment for transthoracic ventricular defibrillation are changing, and physicians must be aware of these developments. The stimulus for these changes has been the recent finding that an important determinant of the amount of electrical energy required to defibrillate is the size of the subject<sup>1</sup>and that most defibrillators commercially available in the late 1960s and early 1970s deliver a peak current that is inadequate to defibrillate many patients who weigh over 80 kg.<sup>1,2</sup> One way to increase defibrillation success is to use defibrillators with higher electrical output. Many of the newer models of
RESUSCITATION
Authors: YANDELL HENDERSON
Journal: JAMA (1934)

<h3>ASPHYXIA NEONATORUM 20</h3> There is no good reason to look, as many writers have done, for any reactions in the neurorespiratory system of a baby, either before or after birth, essentially different from those of an older child or adult. The normal baby starts to breathe under essentially the same stimulus that causes an adult to breathe again after holding his breath. If in the adult the breath holding has been aided by a preliminary period of voluntarily forced ventilation, the analogy is even closer. The reason that the fetus does not breathe in utero is that its blood is too well arterialized to stimulate the fetal neurorespiratory system, which is rather inexcitable so long as the lungs are atelectatic. If respiratory efforts do occur, the thoracic muscles, which are barely strong enough to dilate the lungs with thin air after birth, fail to draw in more than a minute